Truist Securities Reiterates Buy Rating on BioNTech (BNTX) following earnings, management changes
Tweet Send to a Friend
Truist Securities analyst Asthika Goonewardene reiterated a Buy rating and $155.00 price target on BioNTech (NASDAQ: BNTX)The analyst commented, "BNTX’s ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
